1. Loomis D. et al. (2016): Carcinogenicity of drinking coffee, mate, and very hot beverages. Lancet Oncol, 17(7):877-878.
  2. Bravi F. et al. (2007): Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatol, 46:430-435.
  3. Larsson S.C. et al. (2007): Coffee consumption and liver cancer: a meta-analysis.Gastroenterol, 132:1740-1745.
  4. Bravi F. et al. (2013): Coffee reduces risk for hepatocellular carcinoma: An updated meta-analysis. Clin Gastro and Hepatol, 11:1413-1421.
  5. Bravi F. et al. (2017): Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev, 26(5): 368-377.
  6. Saab S. et al. (2014): Impact of coffee on liver disease a systematic review. LiverInt, 34(4):495-504.
  7. Goh G.B. et al. (2014): Coffee, alcohol, and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatol, 60:661-9.
  8. Wadhawan M. and Anandt A.C. (2016): Coffee and Liver Disease. J Clin Exp Hepatol, 6(1): 40–46.
  9. Walton H.B. et al. (2013): An epidemiological study of the association of coffee with chronic liver disease. Scot Med J, 58(4):217-222.
  10. Gressner O.A. (2009): About coffee, cappuccino and connective tissue growth factor – or how to protect your liver!? Enviro Toxicol & Pharmacol, 28(1):1-10.
  11. Modi A.A. et al. (2010): Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatol, 51:201-209.
  12. Catalano D. et al. (2010): Protective role of coffee on non-alcoholic fatty liver disease (NAFLD). Dig Dis & Sci, 55(11):3200-3206.
  13. Birerdinc A. et al. (2012): Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol & Therapeu, 35(1):76-82.
  14. Molloy J.W. et al. (2012): Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatol,55(2):429-36.
  15. Gutierrez-Grobe Y. et al. (2012): High coffee intake is associated with lower grade non-alcoholic fatty liver disease: the role of peripheral antioxidant activity. Annals Hepatol, 11(3):350-355.
  16. Bambha K. et al. (2014): Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int, 34(8):1250-8.
  17. Wijarnpreecha K. et al. (2017): Coffee consumption and risk of non alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastro Hepatol, 29(2):e8-e12.
  18. Shen H. et al. (2016): Association between caffeine consumption and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Therap Adv Gastro, 9(1):113-20.
  19. Hodge A. et al. (2017): Coffee intake is associated with a lower liver stiffness in patients with non-alcoholic fatty liver disease, hepatitis C and hepatitis B. Nutrients, 9(1):56.
  20. Chen Y.P. et al. (2019): A systematic review and a dose-response meta-analysis of coffee dose and non-alcoholic fatty liver disease. Clin Nutr, 38(6):2552-255.
  21. EFSA (2015): Scientific Opinion on the Safety of Caffeine. EFSA J, 13(5):4102.
  22. Freedman N.D. et al. (2009): Coffee intake is associated with lower rates of liver disease progression in chronic Hepatits-C. Hepatol, 50:1360.
  23. Costentin C.E. et al. (2011): Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol, Volume 54; 1123-1129.
  24. Sasaki Y. et al. (2014): Effect of caffeine containing beverage consumption on serum alanine aminotransferase levels in patients with chronic hepatitis C virus infection: a hospital based cohort study. PLoS One, 8(12):e83382.
  25. Gressner O.A. (2009): Less Smad2 is good for you? A scientific update on coffee’s liver benefits. Hepatol, 50, 970-978.
  26. Gressner O.A. et al. (2009): Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in parenchymal cells. Liver Int, 29(6):886-897.
  27. Muriel P. et al. (2010): Coffee and liver disease. Fitoterapia, 81:297-305.
  28. Romualdo G.R. et al. (2019): Drinking for protection? Epidemiological and experimental evidence on the beneficial effects of coffee or major coffee compounds against gastrointestinal and liver. Food Res Int, 123:567-589.
  29. Inoue M. and Tsugane S. (2019): Coffee Drinking and Reduced Risk of Liver Cancer: Update on Epidemiological Findings and Potential Mechanisms. Curr Nutr Rep, 8(3):182-186.
  30. Salomone F. et al. (2017): Molecular Bases Underlying the Hepatoprotective Effects of Coffee. Nutrients, 9(1):85.
  31. Blachier M. et al. (2013): ‘The burden of Liver Disease in Europe: A Review of Available Epidemiological Data’ Available at:
  32. Williams R. et al. (2015): Liver disease in the UK: Startling findings & urgent need for action. J Hepatol, 63:297–299
  33. World Cancer Research Fund (2012): Diet Nutrition, Physical Activity and Liver Cancer. Available at:
  34. Ferlay J. et al. (2010): Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer, 46(4):765–81.
  35. Bray F. et al. (2018): Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin, 68(6):394-424.
  36. Setiawan V.W. et al. (2015): Association of Coffee Intake with Reduced Incidence of Liver Cancer and Death from Chronic Liver Disease in the US Multiethnic Cohort. Gastroenterol, 148(1):118-125.
  37. Bamia C. et al. (2015): Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer, 136(8):1899-908.
  38. Petrick J.L. et al. (2015): Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project. Cancer Epidemiol Biomarkers Prev, 24(9):1398-406.
  39. Lai G.Y. (2013): The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Canc109:1344–1351.
  40. Leung W.W. et al. (2011): Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. .J Epidemiol & Comm Health, 65:556-558.
  41. Jang E.S. et al. (2013): The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int, 33(7):1092-1099.
  42. Kennedy O.J. et al. (2017): Coffee, including caffeinated and decaffeinatedcoffee, and the risk of Hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open, 1136/bmjopen-2016-013739.
  43. Wiltberger G. et al. (2019): Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis. Aliment Pharmacol Ther, 49(6):779-788.
  44. Xiao Q. et al. (2014): Inverse association of total and decaffeinated coffee with liver enzymes in NHANES 1999-2010. Hepatol, 10.1002/hep.27367.
  45. Alferink L.J.M. et al. (2017): Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam Study.J Hepatol, published online ahead of print.
  46. Soleimani D. et al. (2019): Dietary patterns in relation to hepatic fibrosis among patients with non-alcoholic fatty liver disease. Diab, Metab Synd, Obesity, 12:315-324.
  47. Tomic D et al. (2018): Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol, 30(10):1103-1115.
  48. Dranoff J.A. (2017): How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations. Hepatol, 60(2):464-467.

This information is intended for Healthcare professional audiences.
Please consider the environment before printing.